SynthesisThe American journal of gastroenterology2017
Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis.
Synthesis in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Rationale for an Eosinophilic Esophagitis Treat-to-Target Concept.Gastroenterology & hepatology · 2024Article
- Odynophagia and Retrosternal Pain Are Common in Eosinophilic Esophagitis and Associated with an Increased Overall Symptom Severity.Digestive diseases and sciences · 2024Article
- Diagnosis and management of eosinophilic esophagitis and esophageal food impaction in adults : A position paper issued by the Austrian Society of Gastroenterology and Hepatology (ÖGGH).Wiener klinische Wochenschrift · 2024Article
- Endoscopic Features of Eosinophilic Gastrointestinal Diseases.Immunology and allergy clinics of North America · 2024Review
- Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2024Review
- Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes.ImmunoTargets and therapy · 2024Review
- Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies.Current gastroenterology reports · 2023Review
- Eosinophilic esophagitis auxiliary diagnosis based on a peptide ligand to eosinophil cationic protein in esophageal mucus of pediatric patients.Scientific reports · 2022Observational
- A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.Gastroenterology · 2022Article
- A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.The Journal of allergy and clinical immunology · 2022Article
- Article
- Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).The Journal of allergy and clinical immunology · 2022Observational
- Pediatric eosinophilic esophagitis outcomes vary with co-morbid eczema and pollen food syndrome.Frontiers in allergy · 2022Article
- Esophageal Dysphagia in Children: State of the Art and Proposal for a Symptom-Based Diagnostic Approach.Frontiers in pediatrics · 2022Review
- Beyond the Eckardt Score: Patient-Reported Outcomes Measures in Esophageal Disorders.Current gastroenterology reports · 2021Review
- Immunogenetic, Molecular and Microbiotic Determinants of Eosinophilic Esophagitis and Clinical Practice-A New Perspective of an Old Disease.International journal of molecular sciences · 2021Review
- Quality Improvement Initiative to Improve Endoscopic Reassessment of Eosinophilic Esophagitis.JPGN reports · 2021Article
- Review
- Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults.Therapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is no clear consensus regarding the most appropriate measure(s) of eosinophilic esophagitis (EoE) disease activity. We aimed to identify all scoring indices used for the measurement of disease activity in EoE, appraise their operating properties, and discuss their value as outcome measures.
methodsMEDLINE, EMBASE, and CENTRAL (The Cochrane library) were searched from inception to 11 May 2016. Randomized controlled trials (RCTs), cohort, case-control, and cross-sectional studies that reported outcomes to measure EoE disease activity or response to treatment were eligible. Operating properties of histologic, endoscopic, and patient reported/symptomatic and health-related quality of life measures were critically appraised according to guidelines proposed by the United States Food and Drug Administration.
resultsOf 4,373 citations, 130 studies were eligible, of which 20 were RCTs. Although no index met all evaluative criteria, we found that: (1) the EoE histologic scoring system (EoEHSS) is the most valid histologic measure; (2) the Endoscopic Reference Score (EREFS) is the most reliable and responsive endoscopy measure; and (3) the Eosinophilic Esophagitis Activity Index (EEsAI) or the Dysphagia Symptoms Questionnaire (DSQ) had superior construct validity and responsiveness in adults. The Pediatric Quality of Life Inventory EoE was the most valid pediatric symptomatic measure.
conclusionsCurrent evidence supports the use of the EoEHSS and EREFS as measures of histologic and endoscopic EoE disease activity, respectively, and the EEsAI, DSQ, or Pediatric Quality of Life Inventory EoE as measures of adult and pediatric symptoms. Additional research is needed to optimize endpoint configuration to facilitate development of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.